Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase
Yok‐Lam Kwong, Thomas S. Y. Chan, Daryl Tan, et al.
Blood (2017) Vol. 129, Iss. 17, pp. 2437-2442
Open Access | Times Cited: 442

Showing 1-25 of 442 citing articles:

Epstein–Barr Virus and Cancer
Paul J. Farrell
Annual Review of Pathology Mechanisms of Disease (2018) Vol. 14, Iss. 1, pp. 29-53
Closed Access | Times Cited: 429
The diagnosis and management of NK/T-cell lymphomas
Eric Tse, Yok‐Lam Kwong
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 296
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou, Constantinos Alifieris, Dimitrios T. Trafalis
Pharmacology & Therapeutics (2018) Vol. 194, pp. 84-106
Closed Access | Times Cited: 292
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Tammy Song, Maarja-Liisa Nairismägi, Yurike Laurensia, et al.
Blood (2018) Vol. 132, Iss. 11, pp. 1146-1158
Open Access | Times Cited: 262
Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type
Motoko Yamaguchi, Ritsuro Suzuki, Masahiko Oguchi
Blood (2018) Vol. 131, Iss. 23, pp. 2528-2540
Open Access | Times Cited: 199
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
Jie Xiong, Bowen Cui, Nan Wang, et al.
Cancer Cell (2020) Vol. 37, Iss. 3, pp. 403-419.e6
Open Access | Times Cited: 188
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda, Janice M. Mehnert, Kim M. Hirshfield, et al.
JNCI Journal of the National Cancer Institute (2017) Vol. 110, Iss. 3, pp. 316-320
Open Access | Times Cited: 187
Outlooks on Epstein-Barr virus associated gastric cancer
Madiha Naseem, Afsaneh Barzi, Christine Brezden‐Masley, et al.
Cancer Treatment Reviews (2018) Vol. 66, pp. 15-22
Open Access | Times Cited: 185
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Xin Li, Yasong Cheng, Mingzhi Zhang, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 180
Genomic profiling for clinical decision making in lymphoid neoplasms
Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2193-2227
Open Access | Times Cited: 108
How we treat NK/T-cell lymphomas
Eric Tse, Weili Zhao, Jie Xiong, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 76
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Naval Daver, Prajwal Boddu, Guillermo Garcia‐Manero, et al.
Leukemia (2018) Vol. 32, Iss. 5, pp. 1094-1105
Open Access | Times Cited: 161
Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation
Awais Ijaz, Ali Younas Khan, Saad Ullah Malik, et al.
Biology of Blood and Marrow Transplantation (2018) Vol. 25, Iss. 1, pp. 94-99
Open Access | Times Cited: 161
Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma
Anshuman Panda, Aguirre A. de Cubas, Mark N. Stein, et al.
JCI Insight (2018) Vol. 3, Iss. 16
Open Access | Times Cited: 146
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
Olli Dufva, Matti Kankainen, Tiina Kelkka, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 126
Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas
Keisuke Kataoka, Hiroaki Miyoshi, Seiji Sakata, et al.
Leukemia (2019) Vol. 33, Iss. 7, pp. 1687-1699
Open Access | Times Cited: 126
Molecular pathogenic pathways in extranodal NK/T cell lymphoma
Sanjay De Mel, Susan Swee-Shan Hue, Anand D. Jeyasekharan, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 115
Sintilimab: A Promising Anti-Tumor PD-1 Antibody
Lin Zhang, Wuqian Mai, Wenyang Jiang, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 115
Targeting immune checkpoints in hematological malignancies
Basit Salik, Mark J. Smyth, Kyohei Nakamura
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 106
Nivolumab treatment of relapsed/refractory Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis in adults
Pengpeng Liu, Xiangyu Pan, Chong Chen, et al.
Blood (2020) Vol. 135, Iss. 11, pp. 826-833
Open Access | Times Cited: 105
Peripheral T cell lymphomas: from the bench to the clinic
Danilo Fiore, Luca Vincenzo Cappelli, Alessandro Broccoli, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 6, pp. 323-342
Closed Access | Times Cited: 105
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
Seok Jin Kim, Jing Quan Lim, Yurike Laurensia, et al.
Blood (2020) Vol. 136, Iss. 24, pp. 2754-2763
Open Access | Times Cited: 105
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
Stefan K. Barta, Jasmine Zain, Alexander W. MacFarlane, et al.
Clinical Lymphoma Myeloma & Leukemia (2019) Vol. 19, Iss. 6, pp. 356-364.e3
Open Access | Times Cited: 104
Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes
Siok‐Bian Ng, Tae‐Hoon Chung, Seiichi Kato, et al.
Haematologica (2017) Vol. 103, Iss. 2, pp. 278-287
Open Access | Times Cited: 102
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma
Reid W. Merryman, Philippe Armand, Kyle Wright, et al.
Blood Advances (2017) Vol. 1, Iss. 26, pp. 2643-2654
Open Access | Times Cited: 102
Page 1 - Next Page

Scroll to top